Clinical Trial Update: Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy

View source ↗

Summary

A terminated clinical trial assessed the health-economic value of using recombinant activated factor VII for severe postpartum hemorrhage versus standard manage…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Hemorrhage

Drugs mentioned

• NovoSeven RT (Recombinant activated factor VII)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nīmes | Conditions: Health Care Cost, Post Partum Haemorrhage | Status: TERMINATED